Cargando…

IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment course...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atzpodien, J, Kirchner, H, Illiger, H J, Metzner, B, Ukena, D, Schott, H, Funke, P J, Gramatzki, M, Jürgenson, S von, Wandert, T, Patzelt, T, Reitz, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375150/ https://www.ncbi.nlm.nih.gov/pubmed/11710825 http://dx.doi.org/10.1054/bjoc.2001.2076

Ejemplares similares

Metastatic renal carcinoma comprehensive prognostic system
por: Atzpodien, J, et al.
Publicado: (2003)

Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
por: Wittke, F, et al.
Publicado: (1999)

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
por: Atzpodien, J, et al.
Publicado: (2003)

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
por: Hoffmann, R, et al.
Publicado: (1999)

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
por: Atzpodien, J, et al.
Publicado: (2002)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma
por: Royston, P, et al.
Publicado: (2006)

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2005)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
por: Freyer, G, et al.
Publicado: (2000)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
por: Naundorf, H, et al.
Publicado: (2000)

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
por: Taal, B G, et al.
Publicado: (2001)

The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
por: McClay, E F, et al.
Publicado: (2000)

Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania
por: Trinconi, Cristiana T., et al.
Publicado: (2018)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
por: Atzpodien, J, et al.
Publicado: (2006)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
por: Kalbakis, K, et al.
Publicado: (2001)

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
por: Nocera, M, et al.
Publicado: (2000)

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma
por: Wong, N A C S, et al.
Publicado: (2001)

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line
por: Parisot, J P, et al.
Publicado: (1999)

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings
por: Tartour, E, et al.
Publicado: (2000)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells
por: Al-Nabulsi, I, et al.
Publicado: (1999)

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Interferon-α resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells
por: Brinckmann, A, et al.
Publicado: (2002)

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women
por: Daidone, M G, et al.
Publicado: (2000)

Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
por: Ferlini, C, et al.
Publicado: (1999)

Lithium and Tamoxifen Modulate Behavior and Protein Kinase C Activity in the Animal Model of Mania Induced by Ouabain
por: Valvassori, Samira S, et al.
Publicado: (2017)

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
por: Verra, N, et al.
Publicado: (2003)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics
por: Dorhoi, Anca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o9sg2dg9msii5op4n4t5pi8rlg